Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

The Nigeria Natural Medicine Development Agency (NNMDA) has unveiled plans to train five million Nigerian youths in cassava ...

Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its ...

Deep-pocketed investors have adopted a bullish approach towards Cassava Sciences SAVA, and it's something market players ...

Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results.